Navigation Links
YM BioSciences third quarter 2010 operational and financial results
Date:5/13/2010

2010 compared with $3.5 million for the first nine months of fiscal 2009. The increase for the three and nine months ended March 31, 2010 over the comparative periods was due mainly to legal, consulting and investor relations fees related to the acquisition of Cytopia Limited.

Licensing and product development expenses were $4.5 million for the third quarter of fiscal 2010 compared with $3.3 million for the third quarter of fiscal 2009. Licensing and product development expenses were $9.3 million for the first nine months of fiscal 2010 compared with $11.5 million for the first nine months of fiscal 2009. The increase in the current quarter is mainly attributable to the addition of the Australian office, resulting in increased office, travel and salary expenditures.

Costs associated with development activities for nimotuzumab increased by $309 thousand to $1.8 million and decreased by $921 thousand to $3.8 million for the three and nine months ended March 31, 2010, respectively, compared to the same periods in the prior year. The current year's costs were due mainly to the two new clinical trials for non-small cell lung cancer patients ineligible for radical chemotherapy (NSCLC) and brain metastases from non-small cell lung cancer, the ongoing glioma trial, and the new BRI project.

Costs associated with development activities for AeroLEFÒ decreased by $304 thousand to $109 thousand and by $1.1 million to $418 thousand for the three and nine months ended March 31, 2010, respectively, compared the same periods in th
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
2. Regado Biosciences to Present at the BIO International Convention Held in Chicago, Illinois on May 5, 2010
3. YM BioSciences announces controlled equity offering
4. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2010 Financial Results
5. NeoStem, Inc. and ImmuneRegen BioSciences(R) Announce a Collaborative Agreement to Advance Stem Cell Technology
6. Neurocrine Biosciences, Inc. Announces Exercise of Over-Allotment Option for Common Stock Offering
7. YM BioSciences announces AACR acceptance of two nimotuzumab poster presentations
8. Neurocrine Biosciences to Present at the Roth 22nd Annual OC Growth Conference
9. YM BioSciences closes US$17.5 million financing
10. YM BioSciences to raise approximately US$15 million
11. Sangamo BioSciences Announces Presentation at Cowen and Company Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") ... develops and commercializes proprietary technologies and products for advanced ... for the fiscal first quarter ended December  31, 2014. ... dollars (CAD), unless otherwise stated. "During ... from our existing customers and add to our sales ...
(Date:2/26/2015)... 2015 DuPont Executive Vice President James ... research advancements and product launches across the Agriculture and ... Merrill Lynch 2015 Global Agriculture Conference. ... supplies the last two years, long-term demand for agricultural ... the last decade, when demand for corn and soybeans ...
(Date:2/26/2015)... Feb. 26, 2015 The healthcare landscape is rapidly ... Frost & Sullivan will host its 20 th ... , March 8 to 10, at the Hilton San Diego ... This event is a platform for global ... discuss industry disruptions and how to succeed in an uncertain ...
(Date:2/26/2015)... 26, 2015 Innovation is more ... from unexpected parts of the world and transforming ... agriculture to manufacturing to health care, disruption is ... realities and socio-political trends shake the foundations of ... ingredient for CEOs to survive the next wave ...
Breaking Biology Technology:SQI Diagnostics Reports First Quarter Financial Results 2SQI Diagnostics Reports First Quarter Financial Results 3SQI Diagnostics Reports First Quarter Financial Results 4SQI Diagnostics Reports First Quarter Financial Results 5SQI Diagnostics Reports First Quarter Financial Results 6DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 2DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 3DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 4DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 5Embrace the Future of Medical Technologies with Frost & Sullivan 2Embrace the Future of Medical Technologies with Frost & Sullivan 3One Million Acts of Innovation Canada Creates Partnership with The Economist Events’ Innovation Forum 2
... BETHESDA, Md., Sept. 16 American Capital Ltd. (Nasdaq: ... completed the sale of its portfolio company Axygen BioScience Inc., ... Corning Incorporated for approximately $400 million. The total inception ... from the equity invested by American Capital,s affiliated funds under ...
... , SAN MARINO, Calif., Sept. 16 ... biotechnology company Viral Genetics (Pink Sheets: VRAL), will address the ... entitled: "The Impact of Custom Peptides on Chronic Inflammation," will ... is being held at The Loews Santa Monica Beach Hotel ...
... , DAEJEON, South Korea, Sept. 16 ... fully-human monoclonal antibodies for the treatment of cancer and inflammatory ... a Series A financing. OrbiMed,s Caduceus Asia Partners and ... from an international syndicate including Green Cross, Tong Yang and ...
Cached Biology Technology:American Capital Receives $182 Million In Proceeds From Sale of Axygen Bioscience 2American Capital Receives $182 Million In Proceeds From Sale of Axygen Bioscience 3American Capital Receives $182 Million In Proceeds From Sale of Axygen Bioscience 4Viral Genetics' Lead Scientist Dr. M. Karen Newell Will Present at 11th Annual SoCalBio Investor and Partnership Conference 2PharmAbcine Closes USD $6 Million Series A Financing 2PharmAbcine Closes USD $6 Million Series A Financing 3PharmAbcine Closes USD $6 Million Series A Financing 4
(Date:1/22/2015)... MUNICH , January 22, 2015 ... its tenth year  The European Patent Office to present ... Two British nominations to be featured: Christofer Toumazou ... week featuring former finalists and winners of the Award   ...
(Date:1/22/2015)... , Jan. 22, 2015   EyeLock, Inc. , a ... has appointed Steve Gerber to the new role ... be responsible for leading development of mobile platforms and wearable ... of success and innovation in the semiconductor industry to his ...
(Date:12/24/2014)... Dec. 23, 2014  Since its launch in December 2014, the ... the pain of trying to remember their usernames and passwords ... to their smartphones. To assist people who have struggled to ... that created 1U and focuses on redefining identity, announced today ...
Breaking Biology News(10 mins):Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 3EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3
... Dobzhansky, the late great geneticist and evolutionary biologist, said ... the light of evolution." This year marks the ... the 150th anniversary of the publication of the Origin ... by means of natural selection in exquisite detail. Universities, ...
... cancer treatments is the difficulty of aiming these treatments ... the process. But a new study by McMaster University ... therapies and drugs that more carefully target cancer, while ... of the McMaster Stem Cell and Cancer Research Institute ...
... CLEVELANDResearchers from Case Western Reserve University and Yale ... the cause behind why some pregnant women suffer ... signs of an infection. Using gene-cloning techniques, ... bacteria present in women with intra-amniotic inflammations were ...
Cached Biology News:GEN joins Charles Darwin 2009 celebration 2Scientists can now differentiate between healthy cells and cancer cells 2Uncultured bacteria found in amniotic fluids of women who experience preterm births 2
2-min, single-step add-mix-measure assay for luciferase expression and HTS in mammalian cells. Linear detection range: 2 fg to 46 ng luciferase....
Endomorphin-2. Cross reactivity: Endomorphin-1 3%, Met-enkephalin <0.03%, Leu-enkephalin <0.01% and beta-Endorphin <0.01%....
... fosmid (40kb), and large plasmid insert (10-20kb) ... BAC vector. On command 20-50 fold copy ... DNA purification. Available with blue-white screening (pEZ ... the highest insert stability. Kits include electrocompetent ...
... PCRx Enhancer System is used ... to optimize PCR of problematic ... PCRX Enhancer Solution with 10X ... primer specificity broader magnesium concentration ...
Biology Products: